GlassScriptPhysician profile
Clinton H Sutherland
NPI 1487622320
$23,748.29
in general payments reported to CMS, 2019-2025
55 companies · $2,804 in 2025
The $2,804 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,483 · 2020: $2,537 · 2021: $3,318 · 2022: $3,491 · 2023: $3,921 · 2024: $3,195 · 2025: $2,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,919.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,554.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,194.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $2,149.58 | 2019-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $1,904.65 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,881.03 | 2019-2025 | Qulipta, Ubrelvy, Viberzi |
| Glaxosmithkline, LLC. | $1,350.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,187.08 | 2019-2025 | |
| Amgen INC. | $916.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $671.78 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $643.25 | 2019-2024 | Glassia, Aralast, Trintellix |
| Abbott Laboratories | $579.43 | 2020-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $527.92 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $514.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.17 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $385.31 | 2019-2025 | Camzyos, Eliquis |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.